High-dose atorvastatin treatment in patients with peripheral arterial disease: Effects on platelet aggregation, blood rheology and plasma homocysteine

Clinical Hemorheology and Microcirculation

Volumn 47, Issue 4, 2011, Pages 241-251

  Van Der Loo, Bernd ^a   Spring, Silviana ^a   Koppensteiner, Renate ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIVITAMIN K; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; COLLAGEN; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; PYRIDOXINE; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ERYTHROCYTE AGGREGATION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HUMAN; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; FEMALE; HEMORHEOLOGY; HEPTANOIC ACIDS; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION; PROSPECTIVE STUDIES; PYRROLES;

EID: 79959212901     PISSN: 13860291     EISSN: 18758622     Source Type: Journal    
DOI: 10.3233/CH-2011-1386     Document Type: Article

References (42)

1. Anonymous, Ethical guidelines for publication in Clinical Hemorheology and Microcirculation, Clin Hemorheol Microcirc 44 (2010), 1-2
2. I.A. Baker, J. Pickering, P.C. Elwood, A. Bayer and S. Ebrahim, Fibrinogen, viscosity and white blood cell count predict myocardial, but not cerebral infarction: Evidence from the Caerphilly and Speedwell cohort, Thromb Haemost 87 (2002), 421-425. (Pubitemid 34232482)
3. S. Banyai, M. Banyai, J. Falger, M. Jansen, E. Alt, K. Derfler and R. Koppensteiner, Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment, Atherosclerosis 159 (2001), 513-519. (Pubitemid 33127266)
4. O.K. Baskurt, M. Boynard, G.C. Cokelet, P. Connes, B.M. Cooke, S. Forconi, F. Liao, M.R. Hardeman, F. Jung, H.J. Meiselman, G. Nash, N. Nemeth, B. Neu, B. Sandhagen, S. Shin, G. Thurston and J.L. Wautier, International expert panel for standardization of hemorheological methods. New guidelines for hemorheological laboratory techniques, Clin Hemorheol Microcirc 42 (2009), 75-97.
5. Z. Bolaman, G. Kadikoylu, N. Ozgel and C. Yenisey, Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia, J Natl Med Assoc 98 (2006), 1273-1277. (Pubitemid 44167751)
6. I.M. Bolayirli, M. Aslan, H. Balci, T. Altug, M. Hacibekiroglu and A. Seven, Effects of atorvastatin therapy on hyperc-holesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine, Life Sciences 81 (2007), 121-127. (Pubitemid 46921173)
7. R. Clarke, E. Naughten, S. Cahalane, K.O. Sullivan, P. Mathias, T. McCall and I. Graham, The role of free radicals as mediators of endothelial cell injury in hyperhomocysteinemia, Ir J Med Sci 161 (1992), 561-564.
8. T.A. Clarke and L.A. Waskell, The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin, Drug Metab Dispos 31 (2003), 53-59. (Pubitemid 36735258)
9. J. Danesh, R. Collins, R. Peto and G.D. Lowe, Haematocrit, viscosity, erythrocyte sedimentation rate: Meta-analysis of prospective studies of coronary heart disease, Eur Heart J 21 (2000), 515-520. (Pubitemid 30148316)
10. M. Dobreanu, C. Galateanu, A. Simionescu and R. Deac, Effects of atorvastatin on some inflammatory parameters in severe primary hypercholesterolemia, Rom J Intern Med 40 (2002), 61-73.
11. R. Frost, C. Otto, H.C. Geiss, P. Schwandt and K.G. Parhofer, Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia, Am J Cardiol 87 (2001), 44-48. (Pubitemid 32013083)
12. P. Giral, E. Bruckert, N. Jacob, M.J. Chapman, M. Foglietti and G. Turpin, Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia, Atherosclerosis 154 (2001), 421-427. (Pubitemid 32146615)
13. B.M.B. Goessens, Y. van der Graaf, J.K. Olijhoek and F.L.J. Visseren, for the Smart Study Group, The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease, J Vasc Surg 45 (2007), 47-54. (Pubitemid 46043540)
14. H.N. Hodis, W.J. Mack, L. Dustin, P.R. Mahrer, S.P. Azen, R. Detrano, J. Selhub, P.Alaupovic, C.Liu, J. Hwang, A. Wilcox and R.H. Selzer, for the BVAIT Research Group, High-dose B vitamin supplementation and progression of subclinical atherosclerosis. A randomized controlled trial, Stroke 40 (2009), 730-736.
15. H. Kiesewetter, F. Jung, S. Spitzer and E. Wenzel, Die Fliesseigenschaften des Blutes und ihre klinische Bedeutung beim arteriellen Gefässpatienten [The flow properties of blood and their clinical significance in the arterial vascular patient], Internist 30 (1989), 420-428.
16. W. Koenig, M. Sund, E. Ernst, W. Mraz, V. Hombach and U. Keil, Association between rheology and components of lipoproteins in human blood. Results from the MONICA project, Circulation 85 (1992), 2197-2204.
17. T. Kovacevic, B. van der Loo, B. Amann-Vesti, V. Rousson and R. Koppensteiner, Plasma homocysteine and restenosis after femoropopliteal angioplasty, J Endovasc Ther 11 (2004), 302-309. (Pubitemid 38802613)
18. W.C. Lau, L.A. Waskell, P.B. Watkins, C.J. Neer, K. Horowitz, A.S. Hopp, A.R. Tait, D.G. Carville, K.E. Guyer and E.R. Bates, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction, Circulation 107 (2003), 32-37. (Pubitemid 36070929)
19. M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D.A. Palisaitis and J.G. Diodati, Comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease, Eur Heart J 28 (2007), 1702-1708. (Pubitemid 47227104)
20. J. Malik, V. Melenovsky, D. Wichterle, T. Haas, J. Simek, R. Ceska and J. Hradec, Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial FAT), Cardiovasc Res 52 (2001), 290-298. (Pubitemid 33000406)
21. H. Neubauer, B. Gunesdogan, C. Hanefeld, M. Spiecker and A. Mugge, Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study, Eur Heart J 24 (2003), 1744-1749. (Pubitemid 37236863)
22. L. Olivotti, G. Ghigliotti, P. Spallarossa, S. Leslie, P. Rossettin, A. Barsotti and C. Brunelli, High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes, Blood Coagul Fibrinolysis 13 (2002), 315-322.
23. M. Piorkowski, U. Weikert, P.L. Schwimmbeck, P. Martus, H.P. Schultheiss and U. Rauch, ADP induced platelet degran-ulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin, Thromb Haemost 92 (2004), 614-620. (Pubitemid 39248019)
24. S. Polena, M.P. Gupta, H. Shaikh, K. Zazzali, N. Coplan, J. Gintautas, S.S. Labana and D. Soffer, Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4, Proc West Pharmacol Soc 51 (2008), 60-62.
25. H. Refsum, E. Nurk, A.D. Smith, P.M. Ueland, C.G. Gjesdal, I. Bjelland, A. Tverdal, G.S. Tell, O. Nygard and S.E. Vollset, The Hordaland homocysteine study: A community-based study of homocysteine, its determinants, and associations with disease, J Nutr 136 (2006), 1731S-1740S. (Pubitemid 43765389)
26. J. Saw, D.M. Brennan, S.R. Steinhubl, D.L. Bhatt, M. Koon-Hou, K. Fox and E.J. Topol, on behalf of the CHARISMA investigators, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial, J Am Coll Cardiol 50 (2007), 291-295. (Pubitemid 47058889)
27. J. Saw, S.R. Steinhubl, P.B. Berger, D.J. Kereiakes, V.L. Serebruany and D. Brennan, E.J. Topol, for the clopidogrel for the reduction of events during observation (CREDO) investigators, Circulation 108 (2003), 921-924.
28. W.S. Schroeder, L. Ghobrial and P.J. Gandhi, Possible mechanisms of drug-induced aspirin and clopidogrel resistance, J Thromb Thrombolysis 22 (2006), 139-150. (Pubitemid 44473565)
29. S. Spring, R. Simon, B. van der Loo, T. Kovacevic, C. Brockes, V. Rousson, B. Amann-Vesti and R. Koppensteiner, High-dose atorvastatin in peripheral arterial disease (PAD): Effect on endothelial function, intima media thickness and local progression of PAD, Thromb Haemost 98 (2008), 182-189.
30. M.C. Stühlinger, P.S. Tsao, J.H. Her, M. Kimoto, R.F. Balint and J.P. Cooke, Homocysteine impairs the nitric oxide pathway role of asymmetric dimethylarginine, Circulation 104 (2001), 2569-2575. (Pubitemid 33104795)
31. L. Szapary, B. Horvath, Z. Marton, T. Alexy, G. Kesmarky, T. Habon, M. Szots, K. Koltai, I. Juricskay, J. Czopf and K. Toth, Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia, CNS Drugs 18 (2004), 165-172. (Pubitemid 38293800)
32. L. Tang, C. Mamotte, F. van Bockxmeer and R.R. Taylor, The effect of homocysteine on DNA synthesis in cultered human vascular smooth muscle, Atherosclerosis 136 (1998), 169-173. (Pubitemid 28341455)
33. E. Tirnaksiz, B. Pamukcu, H. Oflaz and Y. Nisanci, Effect of high-dose statin therapy on platelet function; statins reduce aspirin resistant platelet aggregation in patients with coronary heart disease, J Thromb Thrombolysis 27 (2009), 24-28.
34. G.H. Tofler, R.B. D'Agostino, P.F. Jacques, A.G. Bostom, P.W. Wilson, I. Lipinska, M.A. Mittleman and J. Selhub, Association between increased homocysteine levels and impaired fibrinolytic potential: Potential mechanism for cardiovascular risk, Thromb Haemost 88 (2002), 799-804. (Pubitemid 35345339)
35. D. Trenk, W. Hochholzer, D. Frundi, C. Stratz, C.M. Valina, H.-P-. Bestehorn, H.J. Büttner and F.J. Neumann, Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600 mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement, Thromb Haemost 99 (2008), 174-181.
36. J. Tsai, M. Perrella, M. Yoshizumi, C.M. Hsieh, E. Haber, R. Schlegel and M.E. Lee, Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis, Proc Natl Acad Sci USA 91 (1994), 6369-6373. (Pubitemid 24200662)
37. I. Tzoulaki, G.D. Murray, A.J. Lee, A. Rumley, G.D. Lowe and F.G.R. Fowkes, Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke. The Edinburgh Artery Study, Circulation 115 (2007), 2119-2127. (Pubitemid 46659063)
38. I. Tzoulaki, G.D. Murray, A.J. Lee, A.Rumley, G.D.O. Lowe and F.G.R. Fowkes, Inflammatory, hemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study, Eur Heart J 28 (2007), 354-362.
39. M. Uyuklu, H.J. Meiselman and O.K. Baskurt, Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties, Clin Hemorheol Microcirc 36 (2007), 25-33. (Pubitemid 46067267)
40. G. Welch and J. Loscalzo, Homocysteine and atherothrombosis, New Engl J Med 338 (1998), 1042-1050. (Pubitemid 128753793)
41. P. Wenaweser, S. Windecker, M. Billinger, S. Cook, M. Togni, B. Meier, A. Haeberli and O.M. Hess, Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis, Am J Cardiol 99 (2007), 353-356. (Pubitemid 46149554)
42. F. Zhang, A. Slungaard, G. Vercellotti and C. Iadecola, Superoxide-dependent cerebrovascular effects of homocysteine, Am J Physiol 274 (1998), R1704-R1711.